Cistanche: The Definitive Guide

What is Cistanche?

Cistanche is not one standardized exposure. New training data use C. deserticola, cognition and fatigue trials combine C. tubulosa with ginkgo, and EFSA did not establish safety for a proposed water extract. EFSA reviewed a Cistanche tubulosa water extract proposed at up to 2 g/day and concluded that safety had not been established. That proposed maximum is not a safe intake level or a dosing recommendation. [1]

Typical Cistanche Protocols

These rows reproduce sources. Do not average them into one universal regimen.

Which forms and label details matter?

Record species (C. deserticola or C. tubulosa), stem material, dry extract or paste, extraction ratio, echinacoside/phenylethanoid specification and every co-ingredient. Ginkgo combinations cannot establish cistanche-alone effects.

How should it be stored?

Follow the label, close the container and protect it from heat, light and moisture.

What is it commonly used for?

Products are marketed for energy, cognition, libido, testosterone, exercise and healthy aging. Human findings are formulation- and population-specific and do not establish a general tonic regimen.

What does human research show?

Tao randomized 48 trained and untrained men to C. deserticola or placebo alongside eight weeks of supervised resistance training. The paper reports strength and biomarker changes, but its abstract and methods conflict on whether extract exposure was 5 g/day or 5 g twice daily; this guide does not resolve that discrepancy by guessing. [2] Kan tested cistanche–ginkgo combinations once daily for 60 days in 190 adults with fatigue symptoms; 175 entered per-protocol analysis, effect sizes were described as trivial, and the two ingredients cannot be separated. [3] Chen likewise tested a cistanche–ginkgo combination for 90 days, not cistanche alone. [4]

How might it act?

Phenylethanoid glycosides such as echinacoside are proposed as marker compounds, but marker content is not proof of a clinical mechanism. Species and co-ingredients change the exposure.

How does it compare with related products?

{compare}

What are the risks and interactions?

EFSA noted 12 exposure-related adverse events across an integrated set of 1,076 vascular-dementia patients at 1,800 mg/day, including cerebral hemorrhage and epilepsy classified as severe, plus major toxicology limitations; it concluded safety was not established. [1] This does not quantify risk for every product, but it rules out treating 2 g/day as an endorsed safe dose. Review seizure history, bleeding risk, neurologic disease, pregnancy, breastfeeding and ginkgo co-exposure.

Which medicines require review?

Have the product reviewed with medicines, before surgery, and during pregnancy or breastfeeding. No universal separation interval is established.

Regulatory status: In the United States, supplements generally lack premarket efficacy approval. In Canada, verify the finished product’s NPN or DIN-HM and licensed conditions. [5], [6]

What should be monitored?

Record product, lot, form, amount per administration, frequency, daily total, co-ingredients, meals, symptoms, medicines, chosen outcome and review date.

What happens when it is stopped?

No ingredient-specific withdrawal syndrome is established. Record the stop date, symptoms and chosen outcome; seek care for a persistent serious symptom.

Seek prompt care for a serious allergic reaction, unusual bleeding, persistent palpitations, chest pain or another severe symptom.

What do public communities report?

Public reports can suggest questions to track, but they do not verify the product, dose or causality. This update did not newly quantify a community sample.

Common questions about Cistanche

Does cistanche improve strength?

One 2025 training trial reported changes, but its dose text conflicts and all participants trained; replication is needed.

What dose did Tao 2025 use?

The paper is internally inconsistent. This guide preserves the conflict instead of guessing.

Do cognition trials prove a cistanche effect?

No. The cited trials combined cistanche with ginkgo.

Did EFSA approve 2 g/day as safe?

No. It was the applicant’s proposed maximum, and EFSA concluded safety was not established.

Are C. deserticola and C. tubulosa interchangeable?

No. Species, extract and marker composition differ.

What should I track?

Species, part, extract ratio, markers, amount each time, frequency, co-ingredients, symptoms and review date.

Glossary

Terms for reading the evidence.

Extract identity

Species, plant part, solvent or ratio, and any standardization used to define a preparation.

Amount per administration

Amount taken at one time, distinct from daily total.

IPSS / AUASI

Questionnaires rating lower urinary tract symptom severity; they do not diagnose the cause.

Qmax

Maximum measured urinary flow rate.

PSA

A prostate-related blood marker; it is not a stand-alone cancer test.

Monotherapy

The ingredient was tested without another active intervention.

How this guide was researched

Accessible official sources and human reports were read on October 9, 2026. Titles, authors, journals, DOI, PMID and visible corrections were checked. An unreported frequency was not guessed.

How this guide was made

Research and drafting were AI-assisted. This draft awaits Doserly editorial review and independent clinical review. See the editorial policy.

Explore the sources